Please assess the completion status of the following clinical trial:

Trial Title: HD18 for Advanced Stages in Hodgkins Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Hodgkin Lymphoma (histologically proven)~* CS (PS) IIB with one or both of the risk factors:~  * bulky mediastinal mass (\> 1/3 of maximum transverse thorax diameter)~ * extranodal involvement~* CS (PS) III, IV~* Written informed consent~Exclusion Criteria:~* Leucocytes \< 3000/µl~* Platelets \< 100000/µl~* Hodgkin´s lymphoma as composite lymphoma~* Activity index (WHO) \< grade 2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): 8 cycles BEACOPPesc
- B (Type: EXPERIMENTAL): 8 cycles BEACOPPesc plus rituximab
- C (Type: ACTIVE_COMPARATOR): 8 cycles BEACOPPesc
- D (Type: EXPERIMENTAL): 4 cycles BEACOPPesc

Based on this trial design, predict the completion outcome and termination type (if applicable).